Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 8Zoledronic Acid 5Therapeutics 5Flow Cytometry 5pembrolizumab 3fludarabine 3Specimen Handling 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Immunologic Techniques 3Gemcitabine 3Amplified Fragment Length Polymorphism Analysis 3venetoclax 2trametinib 2ruxolitinib 2pertuzumab 2palbociclib 2liposomal doxorubicin 2liposomal amphotericin B 2dabrafenib 2copanlisib 2aldesleukin 2abiraterone 2Vorinostat 2Trastuzumab 2Surveys and Questionnaires 2Sunitinib 2Sorafenib 2Rituximab 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × saracatinib × Plasma cell × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡